Tiotropium + olodaterol provides significant lung-function benefits compared to flucticasone + salmeterol regardless of prior bronchodilator use

E Derom; KM Beeh; J Echave-Sustaeta; L Grönke; D Zhai; L Bjermer

doi:10.1055/s-0037-1598309

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000059.xml

Share / Bookmark

Facebook X Linkedin Weibo

Pneumologie 2017; 71(S 01): S1-S125
DOI: 10.1055/s-0037-1598309

Posterbegehung – Sektion Klinische Pneumologie

COPD I – Andreas Rembert Koczulla/Marburg, Henrik Watz/Großhansdorf

Georg Thieme Verlag KG Stuttgart · New York

Tiotropium + olodaterol provides significant lung-function benefits compared to flucticasone + salmeterol regardless of prior bronchodilator use

E Derom

¹Department of Pulmonology, Ghent University Hospital

,

KM Beeh

²Respiratory Research Institute GmbH

,

J Echave-Sustaeta

³Hospital Universitario Quirón Madrid

,

L Grönke

⁴Boehringer Ingelheim Pharma GmbH & Co. KG

,

D Zhai

⁵Inventiv Health Clinical

,

L Bjermer

⁶Skane University Hospital

› Author Affiliations

Further Information

Publication History

Publication Date:
23 February 2017 (online)

Also available at

Introduction:

The ENERGITO® study demonstrated superior lung function with long-acting muscarinic antagonist (LAMA) tiotropium + long-acting β₂-agonist (LABA) olodaterol (T+O) compared to inhaled corticosteroid (ICS) fluticasone + LABA salmeterol (F+S) in patients with COPD.

Aim:

To investigate if lung-function benefits of T+O compared to F+S were affected by prior ICS, LAMA or LABA treatment in ENERGITO®.

Methods:

In ENERGITO® (1237.11, NCT01969721; Phase IIIb, randomised, double-blind), patients with moderate to severe COPD received once-daily T+O 2.5/5 or 5/5 µg and twice-daily F+S 250/50 or 500/50 µg for 6 weeks. A post hoc analysis evaluated FEV₁ AUC_{0 – 12} and AUC_{0 – 24} responses in patients with or without LAMA, LABA or ICS therapy at screening.

Results:

229 patients were enrolled and treated: 123 received prior LAMA, 141 LABA, 109 ICS. T+O significantly improved FEV₁ AUC_{0 – 12} and AUC_{0 – 24} responses in patients with or without prior LAMA, LABA or ICS therapy compared to F+S (Table).

Conclusions:

In ENERGITO®, patients with moderate or severe COPD showed improved lung function with T+O compared to F+S regardless of prior treatment. T+O is a better choice than LABA/ICS to optimise lung function when initiating maintenance treatment.

Funding:

Boehringer Ingelheim

Tab. 1
	Treatment difference
	Adjusted mean FEV₁ AUC_{0 – 12} response, L (SE)
	Prior LAMA	No LAMA	Prior LABA	No LABA	Prior ICS	No ICS
T+O 5/5 µg vs. F+S 250/50 µg T+O 5/5 µg vs. F+S 500/50 µg	0.121^a (0.016) 0.130^a (0.016)	0.129^a (0.016) 0.127^a (0.016)	0.123^a (0.012) 0.137^a (0.012)	0.128^a (0.021) 0.118^a (0.021)	0.129^a (0.013) 0.139^a (0.013)	0.123^a (0.017) 0.120^a (0.017)
	Adjusted mean FEV₁ AUC_{0 – 24} response, L (SE)
	Prior LAMA	No LAMA	Prior LABA	No LABA	Prior ICS	No ICS
T+O 5/5 µg vs. F+S 250/50 µg T+O 5/5 µg vs. F+S 500/50 µg	0.083^a (0.015) 0.092^a (0.015)	0.081^a (0.016) 0.079^a (0.015)	0.083^a (0.012) 0.096^a (0.012)	0.082^a (0.020) 0.072^a (0.020)	0.084^a (0.013) 0.099^a (0.012)	0.081^a (0.017) 0.076^a (0.017)
^ap < 0.001 SE, standard error

Content already presented at ERS congress 2016

#

No conflict of interest has been declared by the author(s).